Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 626

1.

Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.

Tibes R, Borad MJ, Dutcus CE, Reyderman L, Feit K, Eisen A, Verbel DA, Von Hoff DD.

Br J Cancer. 2018 Jun;118(12):1580-1585. doi: 10.1038/s41416-018-0099-5. Epub 2018 Jun 5.

PMID:
29867224
2.

Phase I Study of CC-486 Alone and in Combination With Carboplatin or nab‑paclitaxel in Patients With Relapsed or Refractory Solid Tumors.

Von Hoff DD, Rasco DW, Heath EI, Munster PN, Schellens JHM, Isambert N, Le Tourneau C, O'Neil BH, Mathijssen RH, Lopez-Martin JA, Edenfield WJ, Martín M, LoRusso PM, Bray GL, DiMartino J, Nguyen A, Liu K, Laille E, Bendell JC.

Clin Cancer Res. 2018 May 15. pii: clincanres.3716.2017. doi: 10.1158/1078-0432.CCR-17-3716. [Epub ahead of print]

PMID:
29764853
3.

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.

Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK.

Br J Cancer. 2018 Jan;118(2):e3. doi: 10.1038/bjc.2017.438.

4.

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.

Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT.

J Gastrointest Oncol. 2017 Dec;8(6):925-935. doi: 10.21037/jgo.2017.09.05.

5.

CBP501 inhibits EGF-dependent cell migration, invasion and epithelial-to-mesenchymal transition of non-small cell lung cancer cells by blocking KRas to calmodulin binding.

Saito N, Mine N, Kufe DW, Von Hoff DD, Kawabe T.

Oncotarget. 2017 Jun 22;8(43):74006-74018. doi: 10.18632/oncotarget.18598. eCollection 2017 Sep 26.

6.

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours.

Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK.

Br J Cancer. 2018 Jan;118(2):153-161. doi: 10.1038/bjc.2017.327. Epub 2017 Sep 26. Erratum in: Br J Cancer. 2018 Jan;118(2):e3.

7.

Preparation and Metabolic Assay of 3-dimensional Spheroid Co-cultures of Pancreatic Cancer Cells and Fibroblasts.

Noel P, Muñoz R, Rogers GW, Neilson A, Von Hoff DD, Han H.

J Vis Exp. 2017 Aug 23;(126). doi: 10.3791/56081.

8.

Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer.

Whatcott CJ, Ng S, Barrett MT, Hostetter G, Von Hoff DD, Han H.

PLoS One. 2017 Aug 25;12(8):e0183871. doi: 10.1371/journal.pone.0183871. eCollection 2017.

9.

18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer.

Korn RL, Von Hoff DD, Borad MJ, Renschler MF, McGovern D, Curtis Bay R, Ramanathan RK.

Cancer Imaging. 2017 Aug 3;17(1):23. doi: 10.1186/s40644-017-0125-5.

10.

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment.

Mun EJ, Babiker HM, Weinberg U, Kirson ED, Von Hoff DD.

Clin Cancer Res. 2018 Jan 15;24(2):266-275. doi: 10.1158/1078-0432.CCR-17-1117. Epub 2017 Aug 1. Review.

PMID:
28765323
11.

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Weiss GJ, Jameson G, Von Hoff DD, Valsasina B, Davite C, Di Giulio C, Fiorentini F, Alzani R, Carpinelli P, Di Sanzo A, Galvani A, Isacchi A, Ramanathan RK.

Invest New Drugs. 2018 Feb;36(1):85-95. doi: 10.1007/s10637-017-0491-7. Epub 2017 Jul 20.

PMID:
28726132
12.

Clinical study of genomic drivers in pancreatic ductal adenocarcinoma.

Barrett MT, Deiotte R, Lenkiewicz E, Malasi S, Holley T, Evers L, Posner RG, Jones T, Han H, Sausen M, Velculescu VE, Drebin J, O'Dwyer P, Jameson G, Ramanathan RK, Von Hoff DD.

Br J Cancer. 2017 Aug 8;117(4):572-582. doi: 10.1038/bjc.2017.209. Epub 2017 Jul 18.

PMID:
28720843
14.

Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma".

Borazanci E, Dang CV, Robey RW, Bates SE, Chabot JA, Von Hoff DD.

Clin Cancer Res. 2017 Apr 1;23(7):1629-1637. doi: 10.1158/1078-0432.CCR-16-2070. Review.

15.

Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.

Pelzer U, Blanc JF, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, Wan Y, Solem CT, Botteman MF, Yang Y, de Jong FA, Hubner RA.

Br J Cancer. 2017 May 9;116(10):1247-1253. doi: 10.1038/bjc.2017.67. Epub 2017 Mar 28.

16.

Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.

Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez SM, Savage HM, Sampath D, Salphati L, Lin RS, Jin H, Parmar H, Hsu JY, Von Hoff DD, Baselga J.

Cancer Discov. 2017 Jul;7(7):704-715. doi: 10.1158/2159-8290.CD-16-1080. Epub 2017 Mar 22.

17.

The National Cancer Institute R25 Cancer Education Grants Program: A Workshop Report.

Korczak JF, Chung DW, Rosemond E, Von Hoff DD, Haspel RL, Waterbor JW, Chang S, Ramirez AG, Perkins S, Wiest J, Lei M.

J Cancer Educ. 2017 Mar;32(1):3-10. doi: 10.1007/s13187-016-1161-8. Review.

18.

Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib.

Bryce AH, Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, McCullough AE, Hunt KS, Ritacca NR, Barrett MT, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, Stanton ML, Cheville J, Swanson S, Schneider DE, McWilliams RR, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Von Hoff DD, Craig DW, Stewart AK, Carpten JD.

Clin Genitourin Cancer. 2017 Aug;15(4):e727-e734. doi: 10.1016/j.clgc.2016.11.001. Epub 2016 Dec 1. No abstract available.

19.

Case report: whole exome sequencing of primary cardiac angiosarcoma highlights potential for targeted therapies.

Zhrebker L, Cherni I, Gross LM, Hinshelwood MM, Reese M, Aldrich J, Guileyardo JM, Roberts WC, Craig D, Von Hoff DD, Mennel RG, Carpten JD.

BMC Cancer. 2017 Jan 5;17(1):17. doi: 10.1186/s12885-016-3000-z.

20.

Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers.

Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, Ritacca NR, McCullough AE, Barrett MT, Hunt KS, Champion MD, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, McWilliams RR, Lazaridis KN, Ramanathan RK, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Valdez R, Jaroszewski DE, Von Hoff DD, Craig DW, Stewart AK, Carpten JD, Bryce AH.

Sci Rep. 2016 Dec 23;6(1):25. doi: 10.1038/s41598-016-0021-4.

21.

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.

Kunzmann V, Ramanathan RK, Goldstein D, Liu H, Ferrara S, Lu B, Renschler MF, Von Hoff DD.

Pancreas. 2017 Feb;46(2):203-208. doi: 10.1097/MPA.0000000000000742.

22.

Blocking Nerve Growth Factor Signaling Reduces the Neural Invasion Potential of Pancreatic Cancer Cells.

Bapat AA, Munoz RM, Von Hoff DD, Han H.

PLoS One. 2016 Oct 28;11(10):e0165586. doi: 10.1371/journal.pone.0165586. eCollection 2016.

23.

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.

Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Wee Ma W, Reni M, Harris M, Whorf R, Liu H, Shiansong Li J, Manax V, Romano A, Lu B, Goldstein D.

Br J Cancer. 2016 Oct 25;115(9):e13. doi: 10.1038/bjc.2016.306. Epub 2016 Sep 22. No abstract available.

24.

Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma.

Babiker HM, Riaz IB, Shah SR, Von Hoff DD, Borad MJ.

Anticancer Drugs. 2017 Feb;28(2):127-132. doi: 10.1097/CAD.0000000000000437. Review.

PMID:
27685167
25.

Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.

Rajeshkumar NV, Yabuuchi S, Pai SG, Tong Z, Hou S, Bateman S, Pierce DW, Heise C, Von Hoff DD, Maitra A, Hidalgo M.

Br J Cancer. 2016 Aug 9;115(4):442-53. doi: 10.1038/bjc.2016.215. Epub 2016 Jul 21.

26.

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.

Chiorean EG, Von Hoff DD, Tabernero J, El-Maraghi R, Ma WW, Reni M, Harris M, Whorf R, Liu H, Li JS, Manax V, Romano A, Lu B, Goldstein D.

Br J Cancer. 2016 Jul 12;115(2):188-94. doi: 10.1038/bjc.2016.185. Epub 2016 Jun 28. Erratum in: Br J Cancer. 2016 Oct 25;115(9):e13.

27.

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.

Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, Kunzmann V, Liu H, McGovern D, Romano A, Von Hoff DD.

J Gastrointest Oncol. 2016 Jun;7(3):469-78. doi: 10.21037/jgo.2016.01.03.

28.

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.

Ramanathan RK, Korn RL, Chiorean EG, Liu H, Von Hoff DD.

Ann Oncol. 2016 Aug;27(8):1647-8. doi: 10.1093/annonc/mdw177. Epub 2016 May 30. No abstract available.

29.

Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply.

Chen LT, Wang-Gillam A, Von Hoff DD, Bayever E, Belanger B.

Lancet. 2016 May 14;387(10032):1997. doi: 10.1016/S0140-6736(16)30365-8. No abstract available.

PMID:
27203770
30.

Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.

Gelhorn HL, Tong S, McQuarrie K, Vernon C, Hanlon J, Maclaine G, Lenderking W, Ye X, Speck RM, Lackman RD, Bukata SV, Healey JH, Keedy VL, Anthony SP, Wagner AJ, Von Hoff DD, Singh AS, Becerra CR, Hsu HH, Lin PS, Tap WD.

Clin Ther. 2016 Apr;38(4):778-93. doi: 10.1016/j.clinthera.2016.03.008. Epub 2016 Apr 1.

31.

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.

Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, Burris HA 3rd, Hart LL, Low SC, Parsons DM, Zale SE, Summa JM, Youssoufian H, Sachdev JC.

Clin Cancer Res. 2016 Jul 1;22(13):3157-63. doi: 10.1158/1078-0432.CCR-15-2548. Epub 2016 Feb 4.

32.

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A.

Ann Oncol. 2016 Apr;27(4):654-60. doi: 10.1093/annonc/mdw006. Epub 2016 Jan 22.

33.

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

Ramanathan RK, Goldstein D, Korn RL, Arena F, Moore M, Siena S, Teixeira L, Tabernero J, Van Laethem JL, Liu H, McGovern D, Lu B, Von Hoff DD.

Ann Oncol. 2016 Apr;27(4):648-53. doi: 10.1093/annonc/mdw020. Epub 2016 Jan 22.

34.

Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT).

Goldstein D, Von Hoff DD, Moore M, Greeno E, Tortora G, Ramanathan RK, Macarulla T, Liu H, Pilot R, Ferrara S, Lu B.

Eur J Cancer. 2016 Jan;52:85-91. doi: 10.1016/j.ejca.2015.10.017. Epub 2015 Dec 1.

35.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group.

Lancet. 2016 Feb 6;387(10018):545-57. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Erratum in: Lancet. 2016 Feb 6;387(10018):536.

PMID:
26615328
36.

Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review.

Borazanci E, Millis SZ, Korn R, Han H, Whatcott CJ, Gatalica Z, Barrett MT, Cridebring D, Von Hoff DD.

World J Gastrointest Oncol. 2015 Sep 15;7(9):132-40. doi: 10.4251/wjgo.v7.i9.132. Review.

37.

A Qualitative Comparison of Symptoms and Impact of Varying Stages of Basal Cell Carcinoma.

Steenrod AW, Smyth EN, Bush EN, Chang AL, Arron ST, Helfrich YR, Von Hoff DD, Brail LH, Coyne KS.

Dermatol Ther (Heidelb). 2015 Sep;5(3):183-99. doi: 10.1007/s13555-015-0081-6. Epub 2015 Sep 1.

38.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G.

N Engl J Med. 2015 Jul 30;373(5):428-37. doi: 10.1056/NEJMoa1411366.

39.

Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction.

Whatcott CJ, Han H, Von Hoff DD.

Cancer J. 2015 Jul-Aug;21(4):299-306. doi: 10.1097/PPO.0000000000000140. Review.

40.

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

Picozzi VJ, Ramanathan RK, Lowery MA, Ocean AJ, Mitchel EP, O'Neil BH, Guarino MJ, Conkling PR, Cohen SJ, Bahary N, Frank RC, Dragovich T, Bridges BB, Braiteh FS, Starodub AN, Lee FC, Gribbin TE, Richards DA, Lee M, Korn RL, Pandit-Taskar N, Goldsmith SJ, Intenzo CM, Sheikh A, Manzone TC, Horne H, Sharkey RM, Wegener WA, O'Reilly EM, Goldenberg DM, Von Hoff DD.

Eur J Cancer. 2015 Sep;51(14):1857-64. doi: 10.1016/j.ejca.2015.06.119. Epub 2015 Jul 14.

41.

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.

Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, Pierce D, Lopez-Casas PP, Menendez C, Tabernero J, Romano A, Wei X, Lopez-Rios F, Von Hoff DD.

Clin Cancer Res. 2015 Nov 1;21(21):4811-8. doi: 10.1158/1078-0432.CCR-14-3222. Epub 2015 Jul 13. Erratum in: Clin Cancer Res. 2016 Dec 15;22(24):6302.

42.

Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients.

Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban CA, Scharpf R, White JR, O'Dwyer PJ, Allen PJ, Eshleman JR, Thompson CB, Klimstra DS, Linehan DC, Maitra A, Hruban RH, Diaz LA Jr, Von Hoff DD, Johansen JS, Drebin JA, Velculescu VE.

Nat Commun. 2015 Jul 7;6:7686. doi: 10.1038/ncomms8686.

43.

Use of mechanistic models to integrate and analyze multiple proteomic datasets.

Stites EC, Aziz M, Creamer MS, Von Hoff DD, Posner RG, Hlavacek WS.

Biophys J. 2015 Apr 7;108(7):1819-1829. doi: 10.1016/j.bpj.2015.02.030.

44.

Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer.

Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, Hostetter G, Shepard HM, Von Hoff DD, Han H.

Clin Cancer Res. 2015 Aug 1;21(15):3561-8. doi: 10.1158/1078-0432.CCR-14-1051. Epub 2015 Feb 18.

45.

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.

Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD.

J Natl Cancer Inst. 2015 Jan 31;107(2). pii: dju413. doi: 10.1093/jnci/dju413. Print 2015 Feb.

PMID:
25638248
46.

Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

Tabernero J, Chiorean EG, Infante JR, Hingorani SR, Ganju V, Weekes C, Scheithauer W, Ramanathan RK, Goldstein D, Penenberg DN, Romano A, Ferrara S, Von Hoff DD.

Oncologist. 2015 Feb;20(2):143-50. doi: 10.1634/theoncologist.2014-0394. Epub 2015 Jan 12.

47.

Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases.

Gatalica Z, Millis SZ, Vranic S, Bender R, Basu GD, Voss A, Von Hoff DD.

Oncotarget. 2014 Dec 15;5(23):12440-7.

48.

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.

Gatalica Z, Snyder C, Maney T, Ghazalpour A, Holterman DA, Xiao N, Overberg P, Rose I, Basu GD, Vranic S, Lynch HT, Von Hoff DD, Hamid O.

Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70. doi: 10.1158/1055-9965.EPI-14-0654. Epub 2014 Nov 12.

49.

Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.

Infante JR, Weiss GJ, Jones S, Tibes R, Bauer TM, Bendell JC, Hinson JM Jr, Von Hoff DD, Burris HA 3rd, Orlemans EO, Ramanathan RK.

Eur J Cancer. 2014 Nov;50(17):2897-904. doi: 10.1016/j.ejca.2014.07.017. Epub 2014 Sep 25.

PMID:
25262379
50.

An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.

Jotte RM, Von Hoff DD, Braiteh F, Becerra CR, Richards DA, Smith DA, Garbo L, Stephenson J, Conkling PR, Robert-Vizcarrondo F, Chen J, Turner PK, Chow KH, Tai DF, Ilaria R Jr.

Invest New Drugs. 2015 Feb;33(1):148-58. doi: 10.1007/s10637-014-0160-z. Epub 2014 Sep 28.

PMID:
25260842

Supplemental Content

Loading ...
Support Center